BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3390576)

  • 21. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
    Richardson DR; Tran EH; Ponka P
    Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
    Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
    Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aging-related changes in the iron status of skeletal muscle.
    DeRuisseau KC; Park YM; DeRuisseau LR; Cowley PM; Fazen CH; Doyle RP
    Exp Gerontol; 2013 Nov; 48(11):1294-302. PubMed ID: 23994517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
    Becker E; Richardson DR
    J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
    Gao J; Richardson DR
    Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation.
    Hermes-Lima M; Gonçalves MS; Andrade RG
    Mol Cell Biochem; 2001 Dec; 228(1-2):73-82. PubMed ID: 11855743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration.
    Brittenham GM
    Semin Hematol; 1990 Apr; 27(2):112-6. PubMed ID: 2190317
    [No Abstract]   [Full Text] [Related]  

  • 28. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
    Richardson DR
    Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks.
    Hermes-Lima M; Nagy E; Ponka P; Schulman HM
    Free Radic Biol Med; 1998 Nov; 25(8):875-80. PubMed ID: 9840731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron.
    Richardson DR; Mouralian C; Ponka P; Becker E
    Biochim Biophys Acta; 2001 May; 1536(2-3):133-40. PubMed ID: 11406348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration.
    Brittenham GM
    Ann N Y Acad Sci; 1990; 612():315-26. PubMed ID: 2291560
    [No Abstract]   [Full Text] [Related]  

  • 32. A lipophilic iron chelator induces an enhanced proliferation of human erythroleukaemia (HEL) cells.
    Ekblom P; Landschulz W; Andersson LC
    Scand J Haematol; 1986 Mar; 36(3):258-62. PubMed ID: 3458297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II).
    Richardson DR; Hefter GT; May PM; Webb J; Baker E
    Biol Met; 1989; 2(3):161-7. PubMed ID: 2490071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyridoxal Isonicotinoyl Hydrazone Improves Neurological Recovery by Attenuating Ferroptosis and Inflammation in Cerebral Hemorrhagic Mice.
    Zhang H; Wen M; Chen J; Yao C; Lin X; Lin Z; Ru J; Zhuge Q; Yang S
    Biomed Res Int; 2021; 2021():9916328. PubMed ID: 34541001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A lipophilic iron chelator can replace transferrin as a stimulator of cell proliferation and differentiation.
    Landschulz W; Thesleff I; Ekblom P
    J Cell Biol; 1984 Feb; 98(2):596-601. PubMed ID: 6693498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative iron mobilizing actions of deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one, and pyridoxal isonicotinoyl hydrazone in iron hydroxamate-loaded mice.
    Gale GR; Litchenberg WH; Smith AB; Singh PK; Campbell RA; Jones MM
    Res Commun Chem Pathol Pharmacol; 1991 Sep; 73(3):299-313. PubMed ID: 1947443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
    Ponka P; Grady RW; Wilczynska A; Schulman HM
    Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of oral iron chelators assayed in the rat.
    Kim BK; Huebers HA; Finch CA
    Am J Hematol; 1987 Mar; 24(3):277-84. PubMed ID: 3826055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity.
    Richardson DR; Bernhardt PV
    J Biol Inorg Chem; 1999 Jun; 4(3):266-73. PubMed ID: 10439071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.
    Chen YL; Kong X; Xie Y; Hider RC
    J Inorg Biochem; 2018 Mar; 180():194-203. PubMed ID: 29329026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.